Read the ruling here.
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.
BOSTON — A federal court in Massachusetts declined to dismiss a securities class action against Boston Scientific and its executives in connection with allegations that they lied about the success of the company’s new heart valve device, which was later recalled, to prop up stock prices and support insider trading.
Read the ruling here.
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.